+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Liver Cancer Diagnostics Market - Global Forecast 2026-2032- Product Image
Liver Cancer Diagnostics Market - Global Forecast 2026-2032- Product Image
Sale

Liver Cancer Diagnostics Market - Global Forecast 2026-2032

  • Report

  • 187 Pages
  • July 2026
  • Region: Global
  • 360iResearch™
  • ID: 5716289
UP TO OFF until Dec 31st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Liver Cancer Diagnostics Market is projected to reach USD 11.38 Billion in 2026. It is expected to continue growing at a CAGR of 6.81%, reaching USD 16.97 Billion by 2032.

Liver cancer diagnostics is moving from episodic detection toward integrated, risk-based disease surveillance across hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and metastatic liver lesions. The clinical need is substantial: liver cancer remains among the leading causes of cancer mortality worldwide, and outcomes depend heavily on earlier detection, accurate staging, and treatment selection. Diagnostic pathways increasingly combine serum biomarkers such as alpha-fetoprotein, liver function assessment, viral hepatitis testing, ultrasound surveillance, multiphase CT, contrast-enhanced MRI, biopsy, histopathology, immunohistochemistry, and molecular profiling. Demand is shaped by the global burden of chronic hepatitis B, hepatitis C, alcohol-associated liver disease, metabolic dysfunction-associated steatotic liver disease, diabetes, obesity, cirrhosis, and aging populations. The most effective diagnostic ecosystems are those that connect high-risk patient identification, regular surveillance, timely confirmatory imaging, pathology capacity, and multidisciplinary decision-making. As health systems pursue earlier diagnosis and more personalized liver cancer care, the market landscape is increasingly defined by precision diagnostics, workflow efficiency, imaging quality, biomarker validation, and equitable access.

Transformative Shifts in the Liver Cancer Diagnostics Landscape

The liver cancer diagnostics landscape is being reshaped by three major shifts: surveillance expansion, precision oncology adoption, and digital workflow modernization. International clinical guidance supports semiannual surveillance for many high-risk cirrhosis and chronic hepatitis B populations, creating sustained demand for reliable ultrasound access, standardized imaging interpretation, and biomarker-supported triage. At the same time, therapeutic advances are increasing the importance of accurate tumor characterization, including differentiation of hepatocellular carcinoma from cholangiocarcinoma and metastatic disease, assessment of vascular invasion, and identification of molecular alterations where tissue or liquid biopsy is clinically appropriate. Radiology is also evolving through structured reporting, liver imaging algorithms, contrast-enhanced MRI protocols, and improved lesion characterization tools. Pathology laboratories are strengthening immunohistochemistry and molecular testing capabilities to support diagnosis, prognosis, and treatment planning. A parallel shift is occurring in decentralized and lower-resource settings, where point-of-care testing, simplified hepatitis screening, tele-radiology, and referral networks are becoming essential for closing diagnostic gaps. These transformations are collectively moving liver cancer diagnostics from reactive confirmation to proactive, continuous risk management.

Cumulative Impact of Artificial Intelligence on Liver Cancer Diagnostics

Artificial intelligence is becoming a cumulative force across the liver cancer diagnostic pathway, particularly in imaging, risk prediction, pathology, and operational workflow. In radiology, AI-supported tools are being developed to help detect focal liver lesions, segment tumors, quantify liver volume, support radiomics analysis, and improve consistency in CT, MRI, and ultrasound interpretation. In high-risk populations, machine learning models can incorporate clinical variables such as age, sex, cirrhosis status, platelet count, liver enzymes, viral hepatitis status, diabetes, and biomarker trends to identify patients who may benefit from intensified surveillance or faster diagnostic escalation. In pathology, computational image analysis can assist with pattern recognition, tumor grading support, and immunohistochemistry quantification when validated within regulated clinical environments. AI also has operational relevance by prioritizing suspicious imaging studies, reducing reporting bottlenecks, and supporting multidisciplinary tumor board preparation. However, adoption depends on transparent validation, representative datasets, clinician oversight, interoperability with hospital systems, cybersecurity, and regulatory compliance. The most credible AI impact will come from augmenting expert decision-making rather than replacing clinical judgment, with measurable gains in diagnostic consistency, turnaround time, and access.

Key Regional Insights Across Liver Cancer Diagnostics

Asia-Pacific carries a particularly high liver cancer burden, influenced by chronic hepatitis B prevalence, aflatoxin exposure in some settings, rising metabolic disease, and large population bases. China, Japan, South Korea, India, Australia, and Southeast Asian countries are strengthening surveillance programs, imaging capacity, viral hepatitis elimination initiatives, and tertiary oncology referral networks, although rural access and affordability remain uneven. North America is characterized by advanced imaging infrastructure, strong pathology and molecular testing capacity, high adoption of multidisciplinary liver tumor boards, and growing demand linked to metabolic dysfunction-associated steatotic liver disease and cirrhosis surveillance. Latin America faces a mixed burden from viral hepatitis, alcohol-related liver disease, obesity, and variable access to specialist imaging and biopsy services, with Brazil and Mexico serving as important diagnostic capacity centers. Europe benefits from established cancer pathways, hepatitis control efforts, radiology standardization, and strong public health surveillance, while demographic aging and metabolic liver disease continue to increase diagnostic pressure. The Middle East is investing in tertiary care, transplant-linked liver disease programs, and advanced imaging, with diagnostic demand shaped by hepatitis, metabolic risk, and expatriate population health needs. Africa faces the greatest access challenges due to limited imaging availability, pathology shortages, late presentation, hepatitis B endemicity in several regions, and constrained oncology referral infrastructure, making affordable screening, hepatitis vaccination, and diagnostic decentralization critical priorities.

Key Group Insights Across Liver Cancer Diagnostics

Within ASEAN, liver cancer diagnostics are influenced by a substantial hepatitis B burden in several countries, uneven rural access to ultrasound and specialist radiology, and growing investments in oncology centers and hepatitis prevention programs. GCC countries are advancing liver cancer diagnostic capabilities through high-end hospital infrastructure, cross-border specialist care, and expanding imaging and laboratory capacity, while metabolic disease and viral hepatitis history remain important drivers of surveillance demand. The European Union supports more harmonized diagnostic quality through clinical guidelines, cancer registries, public reimbursement systems, hepatitis elimination targets, and increasing use of structured imaging and pathology protocols. BRICS countries represent a highly diverse diagnostic environment: China and India account for large high-risk populations, Brazil and Russia face geographic and system-capacity disparities, and South Africa highlights the need for stronger linkage between hepatitis care, imaging access, pathology, and oncology treatment. G7 countries generally demonstrate strong availability of CT, MRI, pathology, and molecular testing, with current priorities centered on earlier detection in cirrhosis, quality standardization, and integration of AI-enabled workflow tools. NATO member countries overlap substantially with advanced European and North American health systems, where diagnostic resilience, interoperable digital health infrastructure, and access to specialized oncology services are increasingly important for sustained liver cancer care readiness.

Key Country Insights Across Liver Cancer Diagnostics

The United States has a mature liver cancer diagnostics ecosystem supported by broad CT and MRI availability, specialist hepatology networks, pathology capacity, and rising surveillance needs linked to cirrhosis, hepatitis C history, alcohol-associated liver disease, and metabolic dysfunction-associated steatotic liver disease. Canada emphasizes guideline-based surveillance and equitable access across geographically dispersed populations, with telehealth and centralized specialty referral playing important roles. Mexico and Brazil face growing diagnostic demand associated with obesity, diabetes, viral hepatitis, and alcohol-related liver disease, while access to high-quality imaging and pathology varies between urban tertiary centers and underserved regions. In the United Kingdom, Germany, France, Italy, and Spain, liver cancer diagnostics are supported by established public health systems, hepatology expertise, advanced imaging, and cancer pathway governance, with growing emphasis on earlier diagnosis, radiology standardization, and biomarker-informed assessment. Russia has significant diagnostic capacity in major cities but faces regional variation in access and referral efficiency. China remains central to global liver cancer diagnostics because of its large hepatitis B-associated risk population, expanding hospital infrastructure, and increasing use of advanced imaging and molecular testing in urban centers. India is experiencing rising demand from hepatitis, alcohol-related liver disease, and metabolic risk, while access disparities make affordable surveillance and scalable imaging pathways essential. Japan and South Korea are recognized for structured surveillance, strong imaging quality, and high clinical focus on early hepatocellular carcinoma detection, supported by extensive experience with chronic viral hepatitis management. Australia combines advanced diagnostic infrastructure with national cancer control capabilities, while also addressing access needs across remote and Indigenous communities.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize clinically validated diagnostic solutions that improve early detection, shorten time to diagnosis, and integrate seamlessly into hepatology, radiology, pathology, and oncology workflows. Strategic focus areas include enhancing ultrasound quality in surveillance settings, expanding access to contrast-enhanced MRI and multiphase CT where clinically indicated, developing biomarker panels with robust evidence, supporting molecular profiling for appropriate cases, and building AI tools that demonstrate reproducible clinical utility across diverse patient populations. Diagnostic providers should invest in interoperability, structured reporting, quality assurance, and secure data infrastructure to support longitudinal monitoring of high-risk patients. Partnerships with public health programs can strengthen hepatitis B vaccination, hepatitis C testing and treatment linkage, cirrhosis registries, and surveillance adherence. In emerging markets, leaders should design scalable models that combine affordable screening, referral triage, tele-radiology, mobile imaging, and workforce training. Across all regions, the most defensible growth strategies will be those aligned with evidence-based clinical guidelines, regulatory standards, patient access, and measurable improvements in diagnostic accuracy and care coordination.

Research Methodology

This executive summary is based on a structured secondary research approach using verified clinical, regulatory, epidemiological, and public health sources. The methodology emphasizes evidence from international cancer agencies, peer-reviewed medical literature, hepatology and oncology clinical guidelines, national cancer control resources, liver disease surveillance publications, health technology assessment outputs, and publicly available regulatory and reimbursement information. Insights were synthesized across diagnostic modalities, including imaging, serum biomarkers, histopathology, immunohistochemistry, molecular diagnostics, liquid biopsy research, and AI-enabled clinical decision support. Regional, group, and country perspectives were developed by comparing liver cancer burden, hepatitis epidemiology, cirrhosis risk factors, imaging infrastructure, laboratory capacity, guideline adoption, healthcare access, and digital health readiness. The analysis excludes market sizing, market share, revenue estimation, and forecasting, focusing instead on evidence-backed clinical demand drivers, technology adoption patterns, access barriers, and strategic implications for stakeholders.

Conclusion

Liver cancer diagnostics is entering a more integrated era in which early detection, risk stratification, imaging precision, pathology confirmation, molecular insight, and AI-supported workflow efficiency are increasingly connected. The strongest opportunities lie in improving surveillance adherence among high-risk populations, reducing diagnostic delays, expanding access to high-quality imaging and pathology, and validating biomarkers and digital tools in real-world clinical settings. Regional disparities remain significant, particularly where hepatitis burden is high and specialist diagnostic infrastructure is limited. At the same time, advanced health systems are moving toward standardized reporting, multidisciplinary care, and precision oncology integration. Stakeholders that align innovation with clinical evidence, regulatory expectations, affordability, and health system workflows will be best positioned to improve liver cancer detection and support better patient outcomes worldwide.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Liver Cancer Diagnostics Market, by Test Type
7.1. Introduction
7.2. Biomarkers
7.2.1. Genetic Markers
7.2.2. Protein Markers
7.2.2.1. AFP Tests
7.2.2.2. DCP Tests
7.3. Biopsy
7.3.1. Core Needle Biopsy
7.3.2. Fine Needle Aspiration
7.4. Genetic Testing
7.4.1. Next-Generation Sequencing
7.4.2. PCR Analysis
8. Liver Cancer Diagnostics Market, by Technology
8.1. Introduction
8.2. CT Scan
8.3. MRI
8.4. PET
8.5. Ultrasound
9. Liver Cancer Diagnostics Market, by Cancer Type
9.1. Introduction
9.2. Hepatocellular Carcinoma
9.3. Cholangiocarcinoma
9.4. Hepatoblastoma
10. Liver Cancer Diagnostics Market, by End User
10.1. Introduction
10.2. Ambulatory Care
10.3. Diagnostic Centers
10.4. Hospitals
10.5. Research Laboratories
11. Liver Cancer Diagnostics Market, by Disease Stage
11.1. Introduction
11.2. Early-Stage Liver Cancer
11.3. Advanced-Stage Liver Cancer
12. Liver Cancer Diagnostics Market, by Region
12.1. Asia-Pacific
12.2. North America
12.3. Latin America
12.4. Europe
12.5. Middle East
12.6. Africa
13. Liver Cancer Diagnostics Market, by Group
13.1. ASEAN
13.2. GCC
13.3. European Union
13.4. BRICS
13.5. G7
13.6. NATO
14. Liver Cancer Diagnostics Market, by Country
14.1. United States
14.2. Canada
14.3. Mexico
14.4. Brazil
14.5. United Kingdom
14.6. Germany
14.7. France
14.8. Russia
14.9. Italy
14.10. Spain
14.11. China
14.12. India
14.13. Japan
14.14. Australia
14.15. South Korea
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. FPNV Positioning Matrix, 2025
15.3. Market Concentration Analysis, 2025
15.3.1. Concentration Ratio (CR)
15.3.2. Herfindahl Hirschman Index (HHI)
15.4. Recent Developments & Impact Analysis, 2025
15.5. Product Portfolio Analysis, 2025
15.6. Benchmarking Analysis, 2025
16. Company Profiles
16.1. Abbott Laboratories
16.2. AbbVie Inc.
16.3. Argon Medical Devices, Inc.
16.4. AstraZeneca PLC
16.5. Bayer AG
16.6. Becton, Dickinson and Company
16.7. Bio-Rad Laboratories, Inc.
16.8. bioMérieux SA
16.9. Boston Scientific Corporation
16.10. Danaher Corporation
16.11. Epigenomics AG
16.12. F. Hoffmann-La Roche Ltd.
16.13. Gilead Sciences, Inc.
16.14. GlaxoSmithKline plc
16.15. Hologic, Inc.
16.16. Illumina, Inc.
16.17. Intercept Pharmaceuticals, Inc. by Alfasigma S.p.A.
16.18. Merck & Co., Inc.
16.19. Novartis AG
16.20. Pfizer, Inc.
16.21. Siemens Healthineers AG
16.22. Sysmex Corporation
16.23. Takeda Pharmaceutical Company Limited
16.24. Thermo Fisher Scientific Inc.
16.25. Vertex Pharmaceuticals Incorporated
List of Figures
FIGURE 1. GLOBAL LIVER CANCER DIAGNOSTICS MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL LIVER CANCER DIAGNOSTICS MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL LIVER CANCER DIAGNOSTICS MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL LIVER CANCER DIAGNOSTICS MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 6. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025 VS 2032 (%)
FIGURE 7. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2032 (%)
FIGURE 9. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2025 VS 2032 (%)
FIGURE 11. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 13. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2025 VS 2032 (%)
FIGURE 15. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 17. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 19. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 21. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 23. GLOBAL LIVER CANCER DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL BIOMARKERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL BIOMARKERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL GENETIC MARKERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL GENETIC MARKERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL GENETIC MARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL PROTEIN MARKERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL PROTEIN MARKERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL PROTEIN MARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL AFP TESTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL AFP TESTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL AFP TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL DCP TESTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL DCP TESTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL DCP TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL BIOPSY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL BIOPSY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL CORE NEEDLE BIOPSY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL CORE NEEDLE BIOPSY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL CORE NEEDLE BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL FINE NEEDLE ASPIRATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL FINE NEEDLE ASPIRATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL FINE NEEDLE ASPIRATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL GENETIC TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL GENETIC TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL NEXT-GENERATION SEQUENCING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL NEXT-GENERATION SEQUENCING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL NEXT-GENERATION SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL PCR ANALYSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL PCR ANALYSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL PCR ANALYSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL CT SCAN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL CT SCAN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL CT SCAN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL MRI MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL MRI MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL MRI MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL PET MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL PET MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL PET MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL ULTRASOUND MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL ULTRASOUND MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL ULTRASOUND MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL HEPATOCELLULAR CARCINOMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL HEPATOCELLULAR CARCINOMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL HEPATOCELLULAR CARCINOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL CHOLANGIOCARCINOMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL CHOLANGIOCARCINOMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL CHOLANGIOCARCINOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL HEPATOBLASTOMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL HEPATOBLASTOMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL HEPATOBLASTOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL AMBULATORY CARE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL AMBULATORY CARE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL AMBULATORY CARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL DIAGNOSTIC CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL DIAGNOSTIC CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL DIAGNOSTIC CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL RESEARCH LABORATORIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL RESEARCH LABORATORIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL RESEARCH LABORATORIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL EARLY-STAGE LIVER CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL EARLY-STAGE LIVER CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL EARLY-STAGE LIVER CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL ADVANCED-STAGE LIVER CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL ADVANCED-STAGE LIVER CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL ADVANCED-STAGE LIVER CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 81. ASIA-PACIFIC LIVER CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 82. ASIA-PACIFIC LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 83. ASIA-PACIFIC LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
TABLE 84. ASIA-PACIFIC LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2032 (USD MILLION)
TABLE 85. ASIA-PACIFIC LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
TABLE 86. ASIA-PACIFIC LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
TABLE 87. ASIA-PACIFIC LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 88. ASIA-PACIFIC LIVER CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 89. ASIA-PACIFIC LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 90. ASIA-PACIFIC LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
TABLE 91. NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 92. NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 93. NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
TABLE 94. NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2032 (USD MILLION)
TABLE 95. NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
TABLE 96. NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
TABLE 97. NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 98. NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 99. NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 100. NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
TABLE 101. LATIN AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 102. LATIN AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 103. LATIN AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
TABLE 104. LATIN AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2032 (USD MILLION)
TABLE 105. LATIN AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
TABLE 106. LATIN AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
TABLE 107. LATIN AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 108. LATIN AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 109. LATIN AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 110. LATIN AMERICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
TABLE 111. EUROPE LIVER CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 112. EUROPE LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 113. EUROPE LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
TABLE 114. EUROPE LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2032 (USD MILLION)
TABLE 115. EUROPE LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
TABLE 116. EUROPE LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
TABLE 117. EUROPE LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 118. EUROPE LIVER CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 119. EUROPE LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 120. EUROPE LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
TABLE 121. MIDDLE EAST LIVER CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 122. MIDDLE EAST LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 123. MIDDLE EAST LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
TABLE 124. MIDDLE EAST LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2032 (USD MILLION)
TABLE 125. MIDDLE EAST LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
TABLE 126. MIDDLE EAST LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
TABLE 127. MIDDLE EAST LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 128. MIDDLE EAST LIVER CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 129. MIDDLE EAST LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 130. MIDDLE EAST LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
TABLE 131. AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 132. AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 133. AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
TABLE 134. AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2032 (USD MILLION)
TABLE 135. AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
TABLE 136. AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
TABLE 137. AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 138. AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 139. AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 140. AFRICA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
TABLE 141. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 142. ASEAN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 143. ASEAN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 144. ASEAN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
TABLE 145. ASEAN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2032 (USD MILLION)
TABLE 146. ASEAN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
TABLE 147. ASEAN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
TABLE 148. ASEAN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 149. ASEAN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 150. ASEAN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 151. ASEAN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
TABLE 152. GCC LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 153. GCC LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 154. GCC LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
TABLE 155. GCC LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2032 (USD MILLION)
TABLE 156. GCC LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
TABLE 157. GCC LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
TABLE 158. GCC LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 159. GCC LIVER CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 160. GCC LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 161. GCC LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
TABLE 162. EUROPEAN UNION LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 163. EUROPEAN UNION LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 164. EUROPEAN UNION LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
TABLE 165. EUROPEAN UNION LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2032 (USD MILLION)
TABLE 166. EUROPEAN UNION LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
TABLE 167. EUROPEAN UNION LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
TABLE 168. EUROPEAN UNION LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 169. EUROPEAN UNION LIVER CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 170. EUROPEAN UNION LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 171. EUROPEAN UNION LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
TABLE 172. BRICS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 173. BRICS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 174. BRICS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
TABLE 175. BRICS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2032 (USD MILLION)
TABLE 176. BRICS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
TABLE 177. BRICS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
TABLE 178. BRICS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 179. BRICS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 180. BRICS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 181. BRICS LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
TABLE 182. G7 LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 183. G7 LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 184. G7 LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
TABLE 185. G7 LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2032 (USD MILLION)
TABLE 186. G7 LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
TABLE 187. G7 LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
TABLE 188. G7 LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 189. G7 LIVER CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 190. G7 LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 191. G7 LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
TABLE 192. NATO LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 193. NATO LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 194. NATO LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
TABLE 195. NATO LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2032 (USD MILLION)
TABLE 196. NATO LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
TABLE 197. NATO LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
TABLE 198. NATO LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 199. NATO LIVER CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 200. NATO LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 201. NATO LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
TABLE 202. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 203. UNITED STATES LIVER CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 204. UNITED STATES LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 205. UNITED STATES LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
TABLE 206. UNITED STATES LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2032 (USD MILLION)
TABLE 207. UNITED STATES LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
TABLE 208. UNITED STATES LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
TABLE 209. UNITED STATES LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 210. UNITED STATES LIVER CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 211. UNITED STATES LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 212. UNITED STATES LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
TABLE 213. CANADA LIVER CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 214. CANADA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 215. CANADA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
TABLE 216. CANADA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2032 (USD MILLION)
TABLE 217. CANADA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
TABLE 218. CANADA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
TABLE 219. CANADA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 220. CANADA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 221. CANADA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 222. CANADA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
TABLE 223. MEXICO LIVER CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 224. MEXICO LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 225. MEXICO LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
TABLE 226. MEXICO LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2032 (USD MILLION)
TABLE 227. MEXICO LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
TABLE 228. MEXICO LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
TABLE 229. MEXICO LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 230. MEXICO LIVER CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 231. MEXICO LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 232. MEXICO LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
TABLE 233. BRAZIL LIVER CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 234. BRAZIL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 235. BRAZIL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
TABLE 236. BRAZIL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2032 (USD MILLION)
TABLE 237. BRAZIL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
TABLE 238. BRAZIL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
TABLE 239. BRAZIL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 240. BRAZIL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 241. BRAZIL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 242. BRAZIL LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
TABLE 243. UNITED KINGDOM LIVER CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 244. UNITED KINGDOM LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 245. UNITED KINGDOM LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
TABLE 246. UNITED KINGDOM LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2032 (USD MILLION)
TABLE 247. UNITED KINGDOM LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
TABLE 248. UNITED KINGDOM LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
TABLE 249. UNITED KINGDOM LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 250. UNITED KINGDOM LIVER CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 251. UNITED KINGDOM LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 252. UNITED KINGDOM LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
TABLE 253. GERMANY LIVER CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 254. GERMANY LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 255. GERMANY LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
TABLE 256. GERMANY LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2032 (USD MILLION)
TABLE 257. GERMANY LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
TABLE 258. GERMANY LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
TABLE 259. GERMANY LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 260. GERMANY LIVER CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 261. GERMANY LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 262. GERMANY LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
TABLE 263. FRANCE LIVER CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 264. FRANCE LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 265. FRANCE LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
TABLE 266. FRANCE LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2032 (USD MILLION)
TABLE 267. FRANCE LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
TABLE 268. FRANCE LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
TABLE 269. FRANCE LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 270. FRANCE LIVER CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 271. FRANCE LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 272. FRANCE LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
TABLE 273. RUSSIA LIVER CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 274. RUSSIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 275. RUSSIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
TABLE 276. RUSSIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2032 (USD MILLION)
TABLE 277. RUSSIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
TABLE 278. RUSSIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
TABLE 279. RUSSIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 280. RUSSIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 281. RUSSIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 282. RUSSIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
TABLE 283. ITALY LIVER CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 284. ITALY LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 285. ITALY LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
TABLE 286. ITALY LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2032 (USD MILLION)
TABLE 287. ITALY LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
TABLE 288. ITALY LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
TABLE 289. ITALY LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 290. ITALY LIVER CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 291. ITALY LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 292. ITALY LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
TABLE 293. SPAIN LIVER CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 294. SPAIN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 295. SPAIN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
TABLE 296. SPAIN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2032 (USD MILLION)
TABLE 297. SPAIN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
TABLE 298. SPAIN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
TABLE 299. SPAIN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 300. SPAIN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 301. SPAIN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 302. SPAIN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
TABLE 303. CHINA LIVER CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 304. CHINA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 305. CHINA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
TABLE 306. CHINA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2032 (USD MILLION)
TABLE 307. CHINA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
TABLE 308. CHINA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
TABLE 309. CHINA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 310. CHINA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 311. CHINA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 312. CHINA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
TABLE 313. INDIA LIVER CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 314. INDIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 315. INDIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
TABLE 316. INDIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2032 (USD MILLION)
TABLE 317. INDIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
TABLE 318. INDIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
TABLE 319. INDIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 320. INDIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 321. INDIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 322. INDIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
TABLE 323. JAPAN LIVER CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 324. JAPAN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 325. JAPAN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
TABLE 326. JAPAN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2032 (USD MILLION)
TABLE 327. JAPAN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
TABLE 328. JAPAN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
TABLE 329. JAPAN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 330. JAPAN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 331. JAPAN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 332. JAPAN LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
TABLE 333. AUSTRALIA LIVER CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 334. AUSTRALIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 335. AUSTRALIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
TABLE 336. AUSTRALIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2032 (USD MILLION)
TABLE 337. AUSTRALIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
TABLE 338. AUSTRALIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
TABLE 339. AUSTRALIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 340. AUSTRALIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 341. AUSTRALIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 342. AUSTRALIA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
TABLE 343. SOUTH KOREA LIVER CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 344. SOUTH KOREA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 345. SOUTH KOREA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
TABLE 346. SOUTH KOREA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2032 (USD MILLION)
TABLE 347. SOUTH KOREA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
TABLE 348. SOUTH KOREA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
TABLE 349. SOUTH KOREA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 350. SOUTH KOREA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 351. SOUTH KOREA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 352. SOUTH KOREA LIVER CANCER DIAGNOSTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
TABLE 353. GLOBAL LIVER CANCER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2025
TABLE 354. GLOBAL LIVER CANCER DIAGNOSTICS MARKET

Companies Mentioned

  • Abbott Laboratories
  • AbbVie Inc.
  • Argon Medical Devices, Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • bioMérieux SA
  • Boston Scientific Corporation
  • Danaher Corporation
  • Epigenomics AG
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Hologic, Inc.
  • Illumina, Inc.
  • Intercept Pharmaceuticals, Inc. by Alfasigma S.p.A.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer, Inc.
  • Siemens Healthineers AG
  • Sysmex Corporation
  • Takeda Pharmaceutical Company Limited
  • Thermo Fisher Scientific Inc.
  • Vertex Pharmaceuticals Incorporated

Table Information

Report AttributeDetails
No. of Pages187
PublishedJuly 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 11.38 Billion
Forecasted Market Value ( USD ) by 2032 $ 16.97 Billion
Compound Annual Growth Rate6.8%
Regions CoveredGlobal
No. of Companies Mentioned25

Related Topics

Related Reports

Liver Cancer Diagnostics - Global Strategic Business Report - Product Image

Liver Cancer Diagnostics - Global Strategic Business Report

  • Report
  • 275 Pages
  • Global
From
Liver Cancer Diagnostics Market Size, Share & Trends Analysis Report by Test Type (Laboratory Tests, Imaging, Endoscopy, Biopsy), by End-use (Hospitals & Diagnostic Laboratories, Academic & Research Institutes), by Region and Segment Forecasts, 2025-2033 - Product Image

Liver Cancer Diagnostics Market Size, Share & Trends Analysis Report by Test Type (Laboratory Tests, Imaging, Endoscopy, Biopsy), by End-use (Hospitals & Diagnostic Laboratories, Academic & Research Institutes), by Region and Segment Forecasts, 2025-2033

  • Report
  • 150 Pages
  • Global
From
Cancer Diagnostics Market - Technologies, Applications and End-Use Facilities - Product Image

Cancer Diagnostics Market - Technologies, Applications and End-Use Facilities

  • Report
  • 278 Pages
  • Global
From
Liver Cancer Diagnostics Market Report 2026 - Product Image

Liver Cancer Diagnostics Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Pancreatic Cancer Diagnostic Market Size, Share & Trends Analysis Report by Product, Test Type, Cancer Type, End Use, Region, and Growth Forecasts, 2026-2033 - Product Image

Pancreatic Cancer Diagnostic Market Size, Share & Trends Analysis Report by Product, Test Type, Cancer Type, End Use, Region, and Growth Forecasts, 2026-2033

  • Report
  • 150 Pages
  • Global
From

About the Market

The Liver Cancer Diagnostics market is a subset of the larger Diagnostics industry. It is focused on the development and commercialization of tests and technologies used to detect and diagnose liver cancer. These tests can include imaging techniques such as ultrasound, computed tomography (CT) scans, and magnetic resonance imaging (MRI). Additionally, blood tests, biopsies, and other laboratory tests may be used to diagnose liver cancer. The Liver Cancer Diagnostics market is highly competitive, with a range of companies offering products and services. These include Roche Diagnostics, Abbott Laboratories, Siemens Healthineers, Becton Dickinson, and Hologic. Other companies in the market include Agilent Technologies, Bio-Rad Laboratories, and Cepheid. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.